CD8A and neoplasm: Taken together, these data suggest that treatment with cisplatin, CpG and PADRE can lead to the cross-presentation of the tumor antigen, E7, resulting in enhanced tumor antigen-specific CD8+ T cell-mediated immune responses in the tumor loci.